# A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk

Study · id `cardio:ct-nct02044146` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02044146](<https://clinicaltrials.gov/study/NCT02044146>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02044146

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT02044146. Randomized; double masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2016-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT02044146, source copy `cardio:ctgov-nct02044146-2018-10-05`, retrieved 2026-10-31)
- Start date: 2014-09 (registry gives no type) (ClinicalTrials.gov record NCT02044146, source copy `cardio:ctgov-nct02044146-2018-10-05`, retrieved 2026-10-31)
- Primary completion: 2016-10 (actual) (ClinicalTrials.gov record NCT02044146, source copy `cardio:ctgov-nct02044146-2018-10-05`, retrieved 2026-10-31)
- Completion: 2017-06 (actual) (ClinicalTrials.gov record NCT02044146, source copy `cardio:ctgov-nct02044146-2018-10-05`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT02044146, source copy `cardio:ctgov-nct02044146-2018-10-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02044146-2018-10-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
- Acronym: RAPID MANAGE
- Condition: Acute Coronary Syndrome
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): Ticagrelor, Prasugrel, Clopidogrel
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)

## Provenance

Content hash: e4855bdc8bac6cbc53adc6da0712df89102ce8d024ff30e9904438de04f70756
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
